Analysis of individual items on the attention deficit/hyperactivity disorder symptom rating scale in children and adults

The effects of age and sex in pivotal trials of lisdexamfetamine dimesylate

Richard H. Weisler, Lenard A. Adler, Scott H. Kollins, David Goodman, Mohamed Hamdani, Bryan Dirks, Ann C. Childress

Research output: Contribution to journalArticle

Abstract

Background: Attention-deficit/hyperactivity disorder (ADHD) symptom presentation across age and sex has not been fully elucidated. The present post hoc analyses qualitatively explored the baseline levels of ADHD symptomatology across subgroups in two clinical trials of children and adults with ADHD to elucidate differences in participant presentation. The response to treatment was examined to determine patterns of response among items of the ADHD Rating Scale IV. Methods: Exploratory post hoc analyses of ADHD Rating Scale IV item scores were conducted on data from two 4-week placebo-controlled trials in children (6-12 years) and in adults (18-55 years) with ADHD. Baseline and endpoint mean item scores were determined for subgroups defined by age (6-9, 10-12, 18-39, and 40-55 years) and sex. Results: The baseline mean item scores were generally numerically similar for all age-by-sex subgroups. The inattention (IA) items were numerically higher than hyperactivity/impulsivity (H/I) items among older children and adults. The endpoint mean item scores were numerically lower after lisdexamfetamine dimesylate treatment for IA and H/I items in all subgroups. Conclusion: These results suggest that regardless of age or sex, baseline IA and H/I symptom profiles were comparable; however, IA vs H/I symptoms were more severe in older participants. In all age-by-sex subgroups, IA and H/I symptoms appeared to decrease after active treatment.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalNeuropsychiatric Disease and Treatment
Volume10
DOIs
StatePublished - Dec 9 2013

Fingerprint

Attention Deficit Disorder with Hyperactivity
Impulsive Behavior
Lisdexamfetamine Dimesylate
Therapeutics
Placebos
Clinical Trials

Keywords

  • ADHD symptom items

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Analysis of individual items on the attention deficit/hyperactivity disorder symptom rating scale in children and adults : The effects of age and sex in pivotal trials of lisdexamfetamine dimesylate. / Weisler, Richard H.; Adler, Lenard A.; Kollins, Scott H.; Goodman, David; Hamdani, Mohamed; Dirks, Bryan; Childress, Ann C.

In: Neuropsychiatric Disease and Treatment, Vol. 10, 09.12.2013, p. 1-12.

Research output: Contribution to journalArticle

@article{d414d21a05154f878fe2220631e8e30f,
title = "Analysis of individual items on the attention deficit/hyperactivity disorder symptom rating scale in children and adults: The effects of age and sex in pivotal trials of lisdexamfetamine dimesylate",
abstract = "Background: Attention-deficit/hyperactivity disorder (ADHD) symptom presentation across age and sex has not been fully elucidated. The present post hoc analyses qualitatively explored the baseline levels of ADHD symptomatology across subgroups in two clinical trials of children and adults with ADHD to elucidate differences in participant presentation. The response to treatment was examined to determine patterns of response among items of the ADHD Rating Scale IV. Methods: Exploratory post hoc analyses of ADHD Rating Scale IV item scores were conducted on data from two 4-week placebo-controlled trials in children (6-12 years) and in adults (18-55 years) with ADHD. Baseline and endpoint mean item scores were determined for subgroups defined by age (6-9, 10-12, 18-39, and 40-55 years) and sex. Results: The baseline mean item scores were generally numerically similar for all age-by-sex subgroups. The inattention (IA) items were numerically higher than hyperactivity/impulsivity (H/I) items among older children and adults. The endpoint mean item scores were numerically lower after lisdexamfetamine dimesylate treatment for IA and H/I items in all subgroups. Conclusion: These results suggest that regardless of age or sex, baseline IA and H/I symptom profiles were comparable; however, IA vs H/I symptoms were more severe in older participants. In all age-by-sex subgroups, IA and H/I symptoms appeared to decrease after active treatment.",
keywords = "ADHD symptom items",
author = "Weisler, {Richard H.} and Adler, {Lenard A.} and Kollins, {Scott H.} and David Goodman and Mohamed Hamdani and Bryan Dirks and Childress, {Ann C.}",
year = "2013",
month = "12",
day = "9",
doi = "10.2147/NDT.S47087",
language = "English (US)",
volume = "10",
pages = "1--12",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Analysis of individual items on the attention deficit/hyperactivity disorder symptom rating scale in children and adults

T2 - The effects of age and sex in pivotal trials of lisdexamfetamine dimesylate

AU - Weisler, Richard H.

AU - Adler, Lenard A.

AU - Kollins, Scott H.

AU - Goodman, David

AU - Hamdani, Mohamed

AU - Dirks, Bryan

AU - Childress, Ann C.

PY - 2013/12/9

Y1 - 2013/12/9

N2 - Background: Attention-deficit/hyperactivity disorder (ADHD) symptom presentation across age and sex has not been fully elucidated. The present post hoc analyses qualitatively explored the baseline levels of ADHD symptomatology across subgroups in two clinical trials of children and adults with ADHD to elucidate differences in participant presentation. The response to treatment was examined to determine patterns of response among items of the ADHD Rating Scale IV. Methods: Exploratory post hoc analyses of ADHD Rating Scale IV item scores were conducted on data from two 4-week placebo-controlled trials in children (6-12 years) and in adults (18-55 years) with ADHD. Baseline and endpoint mean item scores were determined for subgroups defined by age (6-9, 10-12, 18-39, and 40-55 years) and sex. Results: The baseline mean item scores were generally numerically similar for all age-by-sex subgroups. The inattention (IA) items were numerically higher than hyperactivity/impulsivity (H/I) items among older children and adults. The endpoint mean item scores were numerically lower after lisdexamfetamine dimesylate treatment for IA and H/I items in all subgroups. Conclusion: These results suggest that regardless of age or sex, baseline IA and H/I symptom profiles were comparable; however, IA vs H/I symptoms were more severe in older participants. In all age-by-sex subgroups, IA and H/I symptoms appeared to decrease after active treatment.

AB - Background: Attention-deficit/hyperactivity disorder (ADHD) symptom presentation across age and sex has not been fully elucidated. The present post hoc analyses qualitatively explored the baseline levels of ADHD symptomatology across subgroups in two clinical trials of children and adults with ADHD to elucidate differences in participant presentation. The response to treatment was examined to determine patterns of response among items of the ADHD Rating Scale IV. Methods: Exploratory post hoc analyses of ADHD Rating Scale IV item scores were conducted on data from two 4-week placebo-controlled trials in children (6-12 years) and in adults (18-55 years) with ADHD. Baseline and endpoint mean item scores were determined for subgroups defined by age (6-9, 10-12, 18-39, and 40-55 years) and sex. Results: The baseline mean item scores were generally numerically similar for all age-by-sex subgroups. The inattention (IA) items were numerically higher than hyperactivity/impulsivity (H/I) items among older children and adults. The endpoint mean item scores were numerically lower after lisdexamfetamine dimesylate treatment for IA and H/I items in all subgroups. Conclusion: These results suggest that regardless of age or sex, baseline IA and H/I symptom profiles were comparable; however, IA vs H/I symptoms were more severe in older participants. In all age-by-sex subgroups, IA and H/I symptoms appeared to decrease after active treatment.

KW - ADHD symptom items

UR - http://www.scopus.com/inward/record.url?scp=84890264557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890264557&partnerID=8YFLogxK

U2 - 10.2147/NDT.S47087

DO - 10.2147/NDT.S47087

M3 - Article

VL - 10

SP - 1

EP - 12

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -